Seismic Rumbles Into Clinic With $121m For Novel Immunology Biologics

Series B Cash Will Advance Two Lead Programs

Less than two years after its $101m series A round, Seismic’s machine-learning powered IMPACT platform for biologics drug discovery yielded two clinical trial-ready assets worthy of a $121m series B.

Color Sound Wave on dark Background, technology, and earthquake wave diagram concept
Seismic has two programs in IND-enabling studies • Source: Shutterstock

Artificial intelligence and machine learning-powered technology platforms have increased in number and investor interest based on the potential for AI/ML to shorten the discovery stage of research and development. And as the space continues to mature, Seismic Therapeutic, Inc. has benefitted as investors have sought out concrete examples of quickly generated new product candidates that are differentiated from other therapeutics in development.

Seismic revealed a $121m series B venture capital round on 4 December, which follows a $101m series A round the company announced in February 2022, bringing its total funding to date to $222m

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business